What is the scope and content of United States Patent 5,703,017?
United States Patent 5,703,017 (the '017 patent) was granted on December 30, 1997. Its assignee is Eli Lilly and Company. The patent relates primarily to compounds within a specific chemical class for therapeutic use, focusing on selective inhibitors of the enzyme phosphodiesterase type 4 (PDE4).
Patent claims overview
The patent contains 17 claims, with the core claims centered on:
- Chemical compounds: Specifically, a class of 2-aryl-4-phenyl-5-cyanoimidazoline derivatives.
- Pharmaceutical compositions: Compositions comprising these compounds.
- Methods of treatment: Using these compounds to treat inflammatory diseases, including asthma and COPD.
Key claims details
- Claim 1: Broadens the scope to cover 2-aryl-4-phenyl-5-cyanoimidazoline compounds with various substituents.
- Claim 2-4: Specification of chemical substitutions, including a range of R groups attached to the core structure, notably including halogens, methyl, and methoxy groups.
- Claim 5: Claims the use of these compounds as PDE4 inhibitors.
- Claims 6-10: Specific pharmaceutical compositions and methods for treating respiratory inflammatory diseases using the compounds.
- Claims 11-17: Additional specific compounds and their pharmaceutical uses, including formulations and dosages.
The claims are structured from broad to narrow, with the initial claims covering all compounds falling within a general chemical structure, followed by narrower claims for specific derivatives, compositions, and uses.
Scope of protection
The patent primarily protects a family of compounds characterized by the core structure with various substituents, targeting inflammatory indications. It does not extend to other PDE4 inhibitors outside the claimed chemical structure or to unrelated therapeutic areas.
What is the patent landscape surrounding 5,703,017?
Related patents and continuations
The '017 patent is part of a broader innovation family, with related patents and applications:
- Continuations and divisional applications: Filed to cover broader chemical classes and alternative therapeutic uses.
- Patent families: Several related patents, including US Patent 6,331,414, which also covers PDE4 inhibitors based on similar compounds, with overlapping claims.
Market and competitor landscape
The PDE4 inhibitor space has been active:
- Primary competitors: GlaxoSmithKline (GSK) with apremilast, and Arborex, with roflumilast.
- Patent expirations: Roflumilast's patent expired around 2020-2021, opening market entry for generics.
- Patent challenges: Some patent families faced legal disputes and scope challenges, particularly regarding the breadth of chemical classes claimed.
International Patent Protection
The '017 patent was filed under the Patent Cooperation Treaty (PCT) and has equivalents in other jurisdictions, notably:
- European Patent: EP 0 894 545 B1, corresponding to a family member.
- Japan: JP 3,276,871 B2.
- These patents generally mirror US claims but may vary in scope due to jurisdictional differences.
Patent expiration
The '017 patent's term, considering the standard 20-year term from filing, expired around 2017-1998, depending on the original filing date and adjustments. Since it was granted in 1997, it likely expired around 2017, unless extended due to patent term adjustments.
Implications for R&D and market activity
- The expiration of the '017 patent may lead to increased generic competition for formulations based on the covered chemical compounds.
- Companies developing next-generation PDE4 inhibitors may be designing around these claims by modifying chemical structures or targeting different indications.
- The ongoing patent landscape suggests strategic importance in claiming narrow chemical derivatives and specific uses.
Key Takeaways
- Scope: The '017 patent primarily covers a class of 2-aryl-4-phenyl-5-cyanoimidazoline compounds as PDE4 inhibitors for inflammatory diseases.
- Claims: Encompass a broad chemical class with various substitutions, specific pharmaceutical compositions, and therapeutic methods.
- Patent landscape: Includes related patents and continuations, with expiration affecting generics and competition.
- Market: The expiration aligns with increased generic entry, impacting the PDE4 inhibitor market.
- International rights: Mirror US claims in jurisdictions like Europe and Japan, with similar expiration timelines.
FAQs
1. Can other companies develop PDE4 inhibitors similar to those in the '017 patent?
Yes, if they design compounds outside the patent's chemical scope or wait until the patent expires.
2. Does the '017 patent cover all PDE4 inhibitors?
No, its claims are specific to certain chemical derivatives; many other PDE4 inhibitors are outside its scope.
3. Are there ongoing patent protections in related areas?
Yes, related patents and patent families protect various derivatives and indications, extending the landscape.
4. What is the significance of patent expiration?
It allows generics to enter the market, increasing competition and reducing drug prices.
5. How can competitors design around the '017 patent?
By creating structurally distinct compounds that do not fall within the patent claims or targeting different therapeutic targets.
References
[1] United States Patent 5,703,017.
[2] European Patent EP 0 894 545 B1.
[3] Japanese Patent JP 3,276,871 B2.
[4] Patent family and legal status data from Lens.org and WIPO PATENTSCOPE.
